Prostate Cancer Clinical Trial
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate.
Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening
Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
Participant must not have history of brain metastases.
Participant must not have impaired cardiac function or clinically significant cardiac disease.
Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment.
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
San Antonio Texas, 78229, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.